Screener
GoodRx Holdings, Inc. GDRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: GoodRx Holdings, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001809519-26-000152
FAQ
- What is GoodRx Holdings, Inc.'s cash & equivalents?
- GoodRx Holdings, Inc. (GDRX) reported cash & equivalents of $296.11M in Q2 2026.
- How has GoodRx Holdings, Inc.'s cash & equivalents changed year-over-year?
- GoodRx Holdings, Inc.'s cash & equivalents increased by 5.3% year-over-year, from $281.32M to $296.11M.
- What is the long-term trend for GoodRx Holdings, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), GoodRx Holdings, Inc.'s cash & equivalents has grown at a -23.0% compound annual growth rate (CAGR), from $968.69M to $261.82M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about GoodRx Holdings, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude